SWOG clinical trial number
CTSU/E1912

A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Closed
Phase
Abbreviated Title
Rand PIII Ibrutinib-Based Tx vs. Fludarabine, Cyclophosphamide, Rituximab in Unrelated Youger CLL
Activated
02/15/2014
Participants
CTSU

Research committees

Leukemia

Treatment

Cyclophosphamide Allopurinol Fludarabine Phosphate Rituximab Ibrutinib

Other Clinical Trials

CTSU/A042001
SWOG Clinical Trial Number

A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia

Research Committee(s)
Leukemia
Activated
02/27/2023
Open
Phase
S1925
SWOG Clinical Trial Number

A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.

Research Committee(s)
Leukemia
Lymphoma
Symptom Control and Quality of Life
Activated
12/14/2020
62% Accrual
Accrual
62%
Open
Phase
CTSU/AALL1821
SWOG Clinical Trial Number

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination with Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old with First Relapse

Research Committee(s)
Leukemia
Activated
12/04/2020
Open